Critical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)

Portola Pharmaceuticals (NASDAQ: PTLA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Portola Pharmaceuticals and Oramed Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Portola Pharmaceuticals $31.93 million 100.61 -$251.01 million ($4.55) -12.24
Oramed Pharmaceuticals $2.19 million 54.44 -$11.45 million ($0.96) -9.32

Oramed Pharmaceuticals has higher revenue, but lower earnings than Portola Pharmaceuticals. Portola Pharmaceuticals is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Portola Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Portola Pharmaceuticals and Oramed Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Portola Pharmaceuticals 0 1 7 0 2.88
Oramed Pharmaceuticals 0 0 1 0 3.00

Portola Pharmaceuticals presently has a consensus price target of $65.83, indicating a potential upside of 18.17%. Oramed Pharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 179.33%. Given Oramed Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Oramed Pharmaceuticals is more favorable than Portola Pharmaceuticals.

Insider & Institutional Ownership

85.3% of Portola Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.3% of Oramed Pharmaceuticals shares are owned by institutional investors. 4.9% of Portola Pharmaceuticals shares are owned by company insiders. Comparatively, 27.5% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Portola Pharmaceuticals and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Portola Pharmaceuticals -807.93% -145.12% -78.93%
Oramed Pharmaceuticals N/A -54.96% -29.63%

Summary

Oramed Pharmaceuticals beats Portola Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply